Analysts "see value" in $75 cash-plus bid for Genzyme

Analysts figure Sanofi-Aventis could increase the value of its offer for Genzyme to $75 in cash per share, plus $2 to $3 in contingent value rights, Bloomberg reports; the company's current bid expires at the end of the week. Report

Suggested Articles

Monday, Bernstein analysts echoed what many were probably thinking about Novo Nordisk’s Rybselsus price: “Finally we can stop talking about it.”

Low interest rates and strong stock valuations are two top reasons why U.S. drugmakers are on the move for deals.

Despite a 45% premium offered to Allergan investors through the AbbVie buyout, one investor is suing to block the deal.